Dapagliflozin factory CAS NO.149506-35-4

FOB Price:: USD 3.00-3.00 /Gram Get Latest Price

Min.Order Quantity:: 10 Gram

Purity:: 99.00%

Port:: China main port

Payment Terms:: T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

Dapagliflozin powder
Dapagliflozin price
Dapagliflozin

Quick Details

ProName: Dapagliflozin factory
CasNo: 149506-35-4
Molecular Formula: C21H25ClO6
Appearance: white powder
Application: in research
DeliveryTime: within 3-5 days after receiving the pa...
PackAge: Aluminum foil bag/ as requirements
Port: China main port
ProductionCapacity: 800 Kilogram/Month
Purity: 99.00%
Storage: Store in a cool dry place and keep awa...
Transportation: by air or by sea
LimitNum: 10 Gram

Superiority

inner mongolia yong ming technology co.,ltd--- a worthy to be depended and trusted pharmaceutical intermediates company. we make sure the good quality product and reasonable price. we have the good after-sales service, to solve any kinds of problems, the goal is making every customer satisfy with our company and gain the best reputation.

there are variety of products for your choose. please contact with us at any time.

our promise:

1. good quality product and reasonable price~ make customers happy and save customers’ money

2. delivery product on time~ save customers’ time

3. professional packing~let the customers receive it successfully

4. many payment instruments~convenient to pay

5. service customers forever~ to establish long-term cooperation relationship

welcome to your inquire and suggestions, everyone here do the best for you!

Details

product name: dapagliflozin

cas no: 149506-35-4

molecular formula: c21h25clo6

appearance: white powder

application: research purpose

delivery time: within 1-3 working day

package: 1kg/aluminum foil bag

production capacity: 500 kilogram/month

purity: 98.5%storage: kept in a cool, dry and ventilated place

.transportation: by air

min order: 1 gram

dapagliflozin , the trade name is farxiga in the u.s. and forxiga in the eu and russia. it is a drug of the gliflozin class, used to treat type 2 diabetes. it was developed by bristol-myers squibb in partnership with astrazeneca.

mechanism of action

dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (sglt2) which are responsible for at least 90% of the glucose reabsorption in the kidney. blocking this transporter mechanism causes blood glucose to be eliminated through the urine.in clinical trials, dapagliflozin lowered hba1c by 0.6 versus placebo percentage points when added to metformin.

selectivity

the ic50 for sglt2 is less than one thousandth of the ic50 for sglt1 (1.1 versus 1390 nmol/l), so that the drug does not interfere with intestinal glucose absorption.

research

clinical trials to assess effectiveness for patients with type 1 diabetes are underway.